Cargando…

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)

BACKGROUND: In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced significantly less physical functional decline with 24‐week edaravone vs placebo, followed by open‐label treatment for an additional 24 weeks. METHODS: Outcome (the change in ALS Functional Rating Scale–Revised,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shefner, Jeremy, Heiman‐Patterson, Terry, Pioro, Erik P., Wiedau‐Pazos, Martina, Liu, Shawn, Zhang, Jeffrey, Agnese, Wendy, Apple, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Clinical Research Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004197/ https://www.ncbi.nlm.nih.gov/pubmed/31621933 http://dx.doi.org/10.1002/mus.26740

Ejemplares similares

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]
por: Brooks, Benjamin Rix, et al.
Publicado: (2022)

Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19
por: Brooks, Benjamin Rix, et al.
Publicado: (2021)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021)

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
por: Abe, Koji, et al.
Publicado: (2014)

Edaravone (MCI-186) is effective as a free radical scavenger following arteriovenous sheathotomy for treatment of macular oedema associated with branch retinal vein occlusion
por: Maeno, T, et al.
Publicado: (2009)

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)

Therapeutic Approaches Targeting Protein Aggregation in Amyotrophic Lateral Sclerosis
por: Malik, Ravinder, et al.
Publicado: (2020)

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?
por: Watanabe, Kazutoshi, et al.
Publicado: (2018)

Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
por: Genge, Angela, et al.
Publicado: (2022)

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)

Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients
por: Samadhiya, Swapnil, et al.
Publicado: (2022)

Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023)

Effect of MCI-186 on Lipid Peroxidation in Experimental Traumatic Brain Damage in Rats
por: Baloglu, Murat, et al.
Publicado: (2022)

Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System
por: Vu, Michelle, et al.
Publicado: (2020)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
por: Han, Hee Jo, et al.
Publicado: (2022)

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
por: Cha, Sun Joo, et al.
Publicado: (2022)

Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis
por: Nourelden, Anas Zakarya, et al.
Publicado: (2023)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Park, Jin-Mo, et al.
Publicado: (2022)

Amyotrophic Lateral Sclerosis and Novel Therapeutic Strategies
por: Morrison, Brett, et al.
Publicado: (2012)

Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
por: Ortiz, Juan Fernando, et al.
Publicado: (2020)

In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis
por: Sadr, Ahmad Shahir, et al.
Publicado: (2021)

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses
por: Miller, Robert G., et al.
Publicado: (2022)

Quantifying Disease Progression in Amyotrophic Lateral Sclerosis
por: Simon, Neil G, et al.
Publicado: (2014)

Skeletal muscle in amyotrophic lateral sclerosis
por: Shefner, Jeremy M, et al.
Publicado: (2023)

Using Intensity Modulated Radiation Therapy for the Treatment of Sialorrhea in Amyotrophic Lateral Sclerosis
por: Ati, Shomik, et al.
Publicado: (2022)

Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self‐report scale (Center for Neurologic Study Bulbar Function Scale)
por: Smith, R. A., et al.
Publicado: (2018)

Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial
por: Eishi-Oskouei, Alireza, et al.
Publicado: (2021)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
por: Houzen, Hideki, et al.
Publicado: (2021)

Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis
por: Goldshtein, Hagit, et al.
Publicado: (2020)

Phenotype of Transgenic Mice Carrying a Very Low Copy Number of the Mutant Human G93A Superoxide Dismutase-1 Gene Associated with Amyotrophic Lateral Sclerosis
por: Deitch, Jeffrey S., et al.
Publicado: (2014)

Improving clinical trial outcomes in amyotrophic lateral sclerosis
por: Kiernan, Matthew C., et al.
Publicado: (2020)

Analysis of the US Safety Data for Edaravone (Radicava(®)) From the Third Year After Launch
por: Genge, Angela, et al.
Publicado: (2022)

Pattern of lung function decline in patients with amyotrophic lateral sclerosis: implications for timing of noninvasive ventilation
por: Panchabhai, Tanmay S., et al.
Publicado: (2019)

Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial
por: Smith, Richard, et al.
Publicado: (2017)

Neuropsychological comparison of incident MCI and prevalent MCI
por: Hansen, Allison, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bge3vpg0dghl5p3cqckdm3gvl9